Drugs / CGX1321
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03507998 | Jun 2017 → Apr 2021 | bile duct carcinoma, carcinoma of esophagus, colorectal adenocarcinoma, gastric adenocarcinoma +2 | Curegenix Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT02675946 | Feb 2016 → Mar 2023 | digestive system cancer | Curegenix Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGX1321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03507998 ↗ |
| Route | Oral | “CGX1321 capsules for oral administration” NCT03507998 ↗ |